European Equities Traded in the US as American Depositary Receipts Slide in Thursday Trading

MT Newswires Live
Yesterday

European equities traded in the US as American depositary receipts were sliding late Thursday morning, down 1.31% to 1,760.75 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and internet browser company Opera (OPRA), which rose 4.3% and 4.2%, respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and internet advertising firm Criteo (CRTO), which were up 2.3% and 1.9%, respectively.

The decliners from continental Europe were led by telecommunications company Nokia (NOK) and healthcare tech company Philips (PHG), which dropped 3.8% and 3.7%, respectively. They were followed by biopharmaceutical company argenx (ARGX) and lender Banco Santander (SAN), which lost 3.6% and 2.8%, respectively.

From the UK and Ireland, the gainers were led by biotech company Trinity Biotech (TRIB) and communications firm WPP (WPP), which advanced 6.7% and 4.4%, respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and software firm Endava (DAVA), which increased 3.6% and 3.3%, respectively.

The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biotech company Autolus Therapeutics (AUTL), which fell 10% and 5.5%, respectively. They were followed by medical device maker Smith & Nephew (SNN) and tobacco company British American Tobacco (BTI), which were down 4.1% and 4%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10